Targeting the JAK/STAT Pathway: A Combined Ligand- and Target-Based Approach

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Computational Biology

Background:

• Janus kinases (JAKs) are key mediators of inflammation and immune responses.
• Dysregulation of the JAK-STAT signaling pathway is implicated in autoimmune and inflammatory disorders.

Purpose of the Study:

• To explore the inhibition of the JAK-STAT pathway as a therapeutic strategy.
• To identify novel JAK inhibitors using a computational approach.

Main Methods:

• Utilized molecular topology, docking, and molecular dynamics simulations for virtual screening.
• Performed in vitro evaluation of inhibitory activity against JAK2 for selected compounds.

Main Results:

• Identified two novel chemical scaffolds with inhibitory activity against JAK2.
• Compound 4 (IC50 = 0.81 μM) and Compound 7 (IC50 = 0.64 μM) demonstrated promising JAK2 inhibition.
• Results were compared to the reference drug Tofacitinib (IC50 = 0.031 μM).

Conclusions:

• The identified compounds represent potential novel therapeutics for autoimmune and inflammatory conditions.
• The study validates a computational strategy for discovering JAK inhibitors.